Research & Public Insights
ASSR Healthcare provides evidence-informed research education on plant-derived wellness compounds, including cannabidiol (CBD). The studies below summarize peer-reviewed clinical research and scientific reviews related to common wellness concerns. Findings are still evolving, and results can vary based on dose, formulation, study design, and individual factors.
Educational only. Not medical advice.
Trouble Sleeping
- Study 1: CBD + terpene formulation in insomnia (randomized, double-blind, placebo-controlled crossover)
- Citation: Shannon S, et al. (2019). Cannabidiol in anxiety and sleep: A large case series. Permanente Journal.
(https://pubmed.ncbi.nlm.nih.gov/30624194/) - Study type: Clinical case series
- CBD focus: Oral CBD administration
- Key finding:66.7% of patients reported improved sleep scores within the first month of CBD use.
- Study 2: CBD and sleep regulation mechanisms
- Citation: Babson KA, et al. (2017). Cannabidiol and sleep: A review of the literature. Current Psychiatry Reports.
(https://pubmed.ncbi.nlm.nih.gov/28349316/) - Study type: Narrative review
- CBD focus: CBD interaction with sleep-wake neurobiology
- Key finding: CBD may influence sleep through serotonin signaling, stress reduction, and circadian rhythm modulation.
- Study 3: Review of CBD in anxiety disorders
- Citation: Suraev AS, et al. (2020). Cannabidiol and sleep: An exploratory study. Journal of Clinical Sleep Medicine. (https://pubmed.ncbi.nlm.nih.gov/32111897/)
- Study type: Human observational study
- CBD focus: CBD-dominant formulations
- Key finding: Participants reported improved sleep quality and reduced sleep disturbances.
Anxiety and Stress
- Study 1: CBD reduces anxiety during public speaking in social anxiety disorder (placebo-controlled)
- Citation: Bergamaschi MM, et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology.(https://pubmed.ncbi.nlm.nih.gov/21307846/)
- Study type: Placebo-controlled clinical study
- CBD focus: Oral CBD as the primary compound studied
- Key finding: CBD was associated with reduced anxiety, cognitive impairment, and discomfort during a simulated public speaking task compared with placebo.
- Study 2: Dose-response study in healthy volunteers (randomized, placebo-controlled)
- Citation: Linares IM, et al. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.(https://pubmed.ncbi.nlm.nih.gov/30328956/)
- Study type: Randomized, placebo-controlled
- CBD focus: CBD tested at multiple doses
- Key finding: A 300 mg dose showed anxiolytic effects during public speaking, while lower or higher doses did not show the same effect, suggesting dose sensitivity
- Study 3: Review of CBD in anxiety disorders
- Citation: de Faria Coelho C, et al. (2024). The Impact of Cannabidiol Treatment on Anxiety Disorders. (https://pubmed.ncbi.nlm.nih.gov/39598172/)
- Study type: Review of human studies
- CBD focus: CBD examined across different anxiety-related conditions and dosing approaches
- Key finding: Evidence suggests CBD may reduce anxiety with minimal adverse effects compared with placebo in some studies, but results are mixed and more rigorous RCTs are needed.
General Inflammation and Pain
- Study 1: Topical CBD for thumb basal joint arthritis pain (randomized controlled trial)
- Citation: Heineman JT, et al. (2022). A Randomized Controlled Trial of Topical Cannabidiol for Thumb Basal Joint Arthritis.(https://pubmed.ncbi.nlm.nih.gov/35637038/)
- Study type: Randomized controlled trial
- CBD focus: Topical CBD as the active intervention
- Key finding: Topical CBD was associated with significant improvements in arthritis-related pain and disability without reported adverse events in the trial context.
- Study 2: Transdermal CBD gel in hand osteoarthritis (open-label feasibility)
- Citation: Bawa Z, et al. (2024). An open-label feasibility trial of transdermal cannabidiol for symptomatic hand osteoarthritis.(https://pubmed.ncbi.nlm.nih.gov/38783008/)
- Study type: Open-label feasibility study
- CBD focus: Transdermal CBD gel
- Key finding: Results suggested potential improvements in pain and grip strength, with authors noting the need for randomized controlled trials.
- Study 3: Mechanisms review (anti-inflammatory and antioxidant pathways)
- Citation: Atalay S, et al. (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol.(https://pubmed.ncbi.nlm.nih.gov/31881765/)
- Study type: Scientific review
- CBD focus: Biological mechanisms of CBD related to oxidative stress and inflammation
- Key finding: CBD is reviewed as having anti-inflammatory and antioxidant activity across multiple molecular targets, supporting continued investigation for inflammation-related conditions.
Autism Spectrum Disorder
- Study 1: CBD-rich cannabis extract in children with ASD (randomized, double-blind, placebo-controlled)
- Citation: da Silva Junior EA, et al. (2024). Efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, placebo-controlled trial.(https://pubmed.ncbi.nlm.nih.gov/35617670/)
- Study type: Randomized, double-blind, placebo-controlled
- CBD focus: CBD-rich extract as the primary formulation studied
- Key finding: The trial evaluated efficacy and safety outcomes in ASD, contributing to growing clinical evidence while underscoring the need for standardized endpoints and broader replication.
- Study 2: CBD-rich cannabis treatment outcomes in ASD (clinical assessment study)
- Citation: Hacohen M, et al. (2022). Children and adolescents with ASD treated with CBD-rich cannabis.(https://pubmed.ncbi.nlm.nih.gov/36085294/)
- Study type: Clinical outcomes study (not placebo-controlled)
- CBD focus: CBD-rich cannabis as the primary intervention
- Key finding: Reported improvements were noted in specific domains (including social communication signals), with authors calling for more double-blind placebo-controlled studies.
- Study 3: Systematic review of CBD-rich cannabis in ASD
- Citation: Jawed B, et al. (2024). The Evolving Role of Cannabidiol-Rich Cannabis in ASD (Systematic Review).(https://pmc.ncbi.nlm.nih.gov/articles/PMC11595093/)
- Study type: Systematic review
- CBD focus: CBD-rich preparations across studies
- Key finding: Review summarizes emerging evidence on symptom domains and safety, while emphasizing heterogeneity of products, dosing, and outcome measures.
Alzheimer’s and Cognitive Health
- Study 1: CBD-rich oil reduced agitation in dementia (randomized controlled trial)
- Citation: Hermush V, et al. (2022). Effects of rich cannabidiol oil on behavioral disturbances in dementia (Avidekel): randomized controlled trial.(https://pubmed.ncbi.nlm.nih.gov/36148467/)
- Study type: Randomized controlled trial
- CBD focus: CBD-rich oil as the primary studied preparation
- Key finding: The CBD-rich oil was associated with reduced agitation compared with placebo, with mostly non-serious side effects reported; authors call for larger studies.
- Study 2: Ongoing clinical trial studying CBD for agitation in Alzheimer’s disease
- Citation: ClinicalTrials.gov (NCT06014424). Cannabidiol Medication Intervention Trial (agitation in Alzheimer’s disease).(https://clinicaltrials.gov/study/NCT06014424)
- Study type: Registered clinical trial
- CBD focus: Highly purified CBD as the investigational intervention
- Why it matters: Shows active clinical investigation into CBD for Alzheimer’s-related behavioral symptoms.
- Study 3: Review of CBD mechanisms and clinical trial landscape in Alzheimer’s and dementia
- Citation: Wu S, et al. (2025). Therapeutic Potential for Cannabidiol on Alzheimer’s Disease and dementia-related outcomes.(https://pmc.ncbi.nlm.nih.gov/articles/PMC12733121/)
- Study type: Review (includes discussion of clinical trials and mechanisms)
- CBD focus: Neuroinflammation, microglial modulation, cytokine pathways, and trial summaries
- Key finding: Summarizes proposed neuroprotective pathways and early clinical directions while emphasizing that definitive conclusions require further large trials.
Research Update: Cannabidiol and Neuroinflammatory Studies
Recent peer-reviewed research published in the Journal of Psychiatric Research evaluated the effects of cannabidiol (CBD) on inflammatory response and pain signaling in controlled research settings. Investigators reported measurable reductions in inflammatory markers and observed differences in pain-related outcomes among study subjects.
It is important to note that these findings are derived from controlled experimental conditions and may not directly translate to clinical applications. Ongoing research continues to explore the mechanisms of the endocannabinoid system and its interaction with inflammatory pathways.
ASSR Healthcare shares emerging scientific developments for informational and educational purposes only. The inclusion of this research does not constitute medical advice, diagnosis, treatment recommendations, or product endorsement.
Source: Journal of Psychiatric Research (2026)
Research Disclaimer
ASSR Healthcare provides educational information only. Content is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding medical concerns.